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Chronic Kidney Disease (CKD) places an increasing burden on health care systems, due to its 
increasing prevalence, poor outcomes, and high cost of renal replacement therapy (RRT).1 
Globally, diabetic nephropathy is the leading cause of CKD.2 To date, very few interventions 
have been proven to be effective for slowing the progression of kidney function decline.3 The 
currently used interventions, ACE-inhibitors and Angiotensin Receptor Blockers, are effective 
in slowing the progression of disease, but not all patients respond to these drugs leaving them 
at high residual risk. Novel interventions are thus desired to address the high unmet medical 
need of CKD. 
Clinical outcome trials are required to ultimately establish a drug’s efficacy and safety. 
Currently, the composite of renal replacement therapy (RRT) and doubling of serum creatinine 
is the established hard end point(s) in clinical trials of CKD progression. The decision to start 
RRT is in part based on the filtering capacity of the kidney, and thus based on the serum 
creatinine level which can be measured objectively, but it is also based on a subjective decision 
of the physician and patient depending on patient wellbeing, health insurance, or local 
guidelines. The RRT component is thus a mixture of loss of filtration power as well as other 
factors including the health of the patient. The doubling of serum creatinine component on the 
other hand is purely driven by the filtration capacity of the kidney. These two components of 
the currently used hard renal end point thus reflect different measures but have in common that 
they are late events in the progression of CKD thereby requiring large trials of long duration. 
This may hinder the initiation of new clinical trials in CKD. Alternative end point that has been 
used in clinical trials of CKD progression is the rate of change in glomerular filtration rate 
(eGFR slope). However, eGFR slope is not a clinically meaningful end point as it does not 
directly reflect how a patient feels, functions or how long the patient survives. Thus, each of 
the components of the currently used renal end points have their advantages and disadvantages.  
This thesis aimed to examine the components of the current hard clinical end point for 
clinical trials of CKD progression in order to define the most optimal renal end point for clinical 
trials of CKD. 
The decline in eGFR has been used as an end point to establish drug efficacy. For 
analysis and interpretation of drug efficacy, it is assumed that renal function declines linearly 
over time. However, the paradigm that renal function declines linearly over time has been 
questioned by recent studies. Chapter two compared the eGFR trajectories in a large cohort 
of patients with and without diabetes, at different stages of CKD using a uniform analytical 






approach. The results showed that the vast majority of non-diabetic patients had a linear renal 
function decline. In patients with type 2 diabetes the renal function trajectories tended to 
fluctuate more but the results suggested it is reasonable to assume that the majority of patients 
had a more or less linear renal function decline. Collectively, these data suggested that for 
clinical trial purposes creatinine based end points can be used both in diabetic and non-diabetic 
populations, although in trials of patients with diabetes the nonlinearity proportion should be 
taken into consideration when calculating the power of a clinical trial. 
The slope of eGFR decline appears to be a useful end point and provides more statistical 
power than a dichotomous outcome if the treatment effects on eGFR are uniform (i.e. do not 
depend on the underlying rate of renal function decline). In chapter three we tested whether 
the effects of ARBs on the slope of eGFR are uniform or proportional in patients with type 2 
diabetes and nephropathy. We observed attenuation of both the mean and variability of the 
slope suggesting larger treatment effects in those with faster rate eGFR decline. These results 
indicate that the absence of a treatment effect in the subgroup of patients with a slow 
progressive renal function loss dilutes the greater treatment effect in fast progressors, thereby 
compromising statistical power. Similar observations have been made in the Modification of 
Diet in Renal Disease (MDRD) trial in which it was shown that the intervention, dietary protein 
restriction, exerted proportional treatment effects as well.5 Thus, when designing new trials and 
using eGFR slope as end point, information about the drug’s effect on eGFR slope (i.e. uniform 
or proportional) should ideally be present in order to make a well informed decision whether 
eGFR slope is an appropriate end point to select.  
Doubling of serum creatinine (equivalent to a 57% eGFR decline) is a late event in 
CKD, thus, there is an ongoing discussion in considering lesser declines in eGFR as alternative 
end points for clinical trials to reduce sample sizes, follow-up time, and cost of conducting the 
trial. In chapter four we determined whether adopting lesser decreases in eGFR (20%, 30%, 
or 40%) as an end point would have yielded more end points while maintaining a similar 
magnitude of treatment effects, and whether acute effects on GFR decline would have 
influenced these results in 2 large trials of ARBs. Compared to a doubling of serum creatinine, 
we observed a larger number of alternative end points when adopting lesser eGFR declines as 
end point, leading to greater precision of the estimate of treatment effects. However, we also 
observed attenuation of the magnitude of the treatment effect, which prevented a gain in 
statistical significance. However, when eGFR decline was computed from month 3 of follow-
up rather than from the randomization value, attenuation of the treatment effect was 
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diminished. This result suggest that the attenuation of the treatment effect appears to be due in 
part to acute effects of ARBs on eGFR. The results of this chapter indicate that despite increases 
in precision, use of end points defined by eGFR declines lesser than a doubling of serum 
creatinine may not improve statistical power, particularly in settings in which a drug exerts an 
acute effect on GFR opposite in direction to its chronic effect on eGFR. These results were 
confirmed in a meta-analysis of 43 studies involving 12,821 individuals. The study showed a 
trend towards an attenuation of the treatment effect, in particular with drugs that exert acute 
effects on GFR, which in turn prevented a gain in statistical power.4 It was eventually 
concluded that in the absence of acute eGFR effects a 40% and possibly 30% eGFR decline 
may be a valid end point. The end point of 30% or 40% eGFR decline is now used in new 
clinical trials of CKD progression such as the FIDELIO DKD trial, a clinical trial involving 
4800 patients with diabetic kidney disease and the TESTING trial, a clinical trial determining 
the efficacy of methylprednisolone in 750 patients with IgA Nephropathy. 
In chapter five we first investigated if the initiation of RRT, a composite of different 
measures as described above, is based on reaching a predefined eGFR level in patients with 
type 2 diabetes and nephropathy. We observed a large discrepancy between the time to reach 
a fixed eGFR threshold of 11 ml/min/1.73m2 and the time to RRT. In addition, we showed with 
joint model analyses that the time-varying eGFR holds a stronger association with reaching a 
filtration based end point (eGFR of 11 ml/min/1.73m2) compared to RRT. We then continued 
to show that these effects may have clinical impact as the effect of the ARB irbesartan is smaller 
on the RRT end point compared to an end point purely based on the filtration capacity of the 
kidney (i.e. serum creatinine ≥6.0 mg/dL or fixed eGFR threshold). These data imply that the 
current practice of evaluating renoprotective drugs with a combined RRT and doubling of 
serum creatinine end point does not only characterize the drug effect on the filtration capacity 
of the kidney but on a combination of parameters involving a patient's wellbeing and possibly 
their combination. Unfortunately, in past clinical trials the reasons for initiation of RRT were 
not documented. Future renal protection trials should systematically register this information 
in order to dissect which factors drove the decision of RRT and through which factors the 
drug/intervention exerted its effect. 
 
Conclusion 
How should we combine and interpret all the results from the studies described in this thesis? 
In a clinical trial we would like the renal end point to be representative of renal function. 






However, renal function is a composite of different functions of the kidney: excretion of waste 
products, maintaining extracellular volume control, acid-base control, production and 
conversion of various hormones. The question is whether (1) we should focus on all these 
properties of the kidney, (2) focus only on filtration loss and use a 30%, 40%, or 57% eGFR 
decline as end point being aware of the potential acute eGFR effects, or (3) combine these two. 
We have to realize, however, that each of these options may lead to a different interpretation 
of the drug effect. For example, a drug that improves the tolerance of the patient to withstand 
the consequences of severely compromised renal function may delay the decision of RRT 
(patient does not complain), whereas eGFR continues to decline. One could question whether 
this is “true” renoprotection from a pharmacological point of view. On the other hand, a drug 
may worsen the symptoms of reduced renal function but does slow the progression of eGFR 
decline. In this example the choice of RRT would have led to a potential neutral or harmful 
trial result despite a beneficial effect on the rate of eGFR decline.  
Based on the considerations and studies described in this thesis, we conclude that the 
optimal end point in clinical trials of CKD progression should be a composite end point which 
properly represents the multiple aspects of renal function. We propose that a hard end point in 
clinical trials of CKD progression should consist of an objectively measured component 
reflecting change in filtering capacity as well as the clinically relevant end point of renal 
replacement therapy. The change in filtering capacity could be the traditionally used doubling 
of serum creatinine but alternatives such as a 40% or in some instances 30% eGFR decline can 
be considered. In any case a good balance between the filtering component and RRT 




The results described in this thesis, supported by meta-analyses and simulations,4, 6 suggest that 
a 30 or 40% decline in GFR would be an acceptable alternative end point in clinical trials in 
some circumstances. However, simulation studies have illustrated that the use of a 30% or 40% 
eGFR decline end point is limited at higher baseline GFR,6 and we have shown that for agents 
that cause an “acute effect” on GFR, a 30% or 40% eGFR decline end point may not increase 
statistical power. As such, these alternative end points are less applicable in drug development 
for drugs targeted at earlier stages of kidney disease and for many drugs with potential 
hemodynamic effects. Alternative strategies to overcome these limitations should be 
Interior WeldegiorgisBEW.indd   106 18-09-17   12:06
6107106






diminished. This result suggest that the attenuation of the treatment effect appears to be due in 
part to acute effects of ARBs on eGFR. The results of this chapter indicate that despite increases 
in precision, use of end points defined by eGFR declines lesser than a doubling of serum 
creatinine may not improve statistical power, particularly in settings in which a drug exerts an 
acute effect on GFR opposite in direction to its chronic effect on eGFR. These results were 
confirmed in a meta-analysis of 43 studies involving 12,821 individuals. The study showed a 
trend towards an attenuation of the treatment effect, in particular with drugs that exert acute 
effects on GFR, which in turn prevented a gain in statistical power.4 It was eventually 
concluded that in the absence of acute eGFR effects a 40% and possibly 30% eGFR decline 
may be a valid end point. The end point of 30% or 40% eGFR decline is now used in new 
clinical trials of CKD progression such as the FIDELIO DKD trial, a clinical trial involving 
4800 patients with diabetic kidney disease and the TESTING trial, a clinical trial determining 
the efficacy of methylprednisolone in 750 patients with IgA Nephropathy. 
In chapter five we first investigated if the initiation of RRT, a composite of different 
measures as described above, is based on reaching a predefined eGFR level in patients with 
type 2 diabetes and nephropathy. We observed a large discrepancy between the time to reach 
a fixed eGFR threshold of 11 ml/min/1.73m2 and the time to RRT. In addition, we showed with 
joint model analyses that the time-varying eGFR holds a stronger association with reaching a 
filtration based end point (eGFR of 11 ml/min/1.73m2) compared to RRT. We then continued 
to show that these effects may have clinical impact as the effect of the ARB irbesartan is smaller 
on the RRT end point compared to an end point purely based on the filtration capacity of the 
kidney (i.e. serum creatinine ≥6.0 mg/dL or fixed eGFR threshold). These data imply that the 
current practice of evaluating renoprotective drugs with a combined RRT and doubling of 
serum creatinine end point does not only characterize the drug effect on the filtration capacity 
of the kidney but on a combination of parameters involving a patient's wellbeing and possibly 
their combination. Unfortunately, in past clinical trials the reasons for initiation of RRT were 
not documented. Future renal protection trials should systematically register this information 
in order to dissect which factors drove the decision of RRT and through which factors the 
drug/intervention exerted its effect. 
 
Conclusion 
How should we combine and interpret all the results from the studies described in this thesis? 
In a clinical trial we would like the renal end point to be representative of renal function. 






However, renal function is a composite of different functions of the kidney: excretion of waste 
products, maintaining extracellular volume control, acid-base control, production and 
conversion of various hormones. The question is whether (1) we should focus on all these 
properties of the kidney, (2) focus only on filtration loss and use a 30%, 40%, or 57% eGFR 
decline as end point being aware of the potential acute eGFR effects, or (3) combine these two. 
We have to realize, however, that each of these options may lead to a different interpretation 
of the drug effect. For example, a drug that improves the tolerance of the patient to withstand 
the consequences of severely compromised renal function may delay the decision of RRT 
(patient does not complain), whereas eGFR continues to decline. One could question whether 
this is “true” renoprotection from a pharmacological point of view. On the other hand, a drug 
may worsen the symptoms of reduced renal function but does slow the progression of eGFR 
decline. In this example the choice of RRT would have led to a potential neutral or harmful 
trial result despite a beneficial effect on the rate of eGFR decline.  
Based on the considerations and studies described in this thesis, we conclude that the 
optimal end point in clinical trials of CKD progression should be a composite end point which 
properly represents the multiple aspects of renal function. We propose that a hard end point in 
clinical trials of CKD progression should consist of an objectively measured component 
reflecting change in filtering capacity as well as the clinically relevant end point of renal 
replacement therapy. The change in filtering capacity could be the traditionally used doubling 
of serum creatinine but alternatives such as a 40% or in some instances 30% eGFR decline can 
be considered. In any case a good balance between the filtering component and RRT 




The results described in this thesis, supported by meta-analyses and simulations,4, 6 suggest that 
a 30 or 40% decline in GFR would be an acceptable alternative end point in clinical trials in 
some circumstances. However, simulation studies have illustrated that the use of a 30% or 40% 
eGFR decline end point is limited at higher baseline GFR,6 and we have shown that for agents 
that cause an “acute effect” on GFR, a 30% or 40% eGFR decline end point may not increase 
statistical power. As such, these alternative end points are less applicable in drug development 
for drugs targeted at earlier stages of kidney disease and for many drugs with potential 
hemodynamic effects. Alternative strategies to overcome these limitations should be 
Interior WeldegiorgisBEW.indd   107 18-09-17   12:06
109108






investigated. One of these strategies include assessing changes in albuminuria as a potential 
surrogate end point or assess alternative approaches of using eGFR decline or a combination 
of these. Albuminuria has been proposed as surrogate outcome7 but the debate as to whether it 
is a valid surrogate end point continues.8 At higher GFR, a trial design to compare mean slopes 
of GFR decline versus time between randomized groups may have greater statistical power 
than comparison of time to a GFR decline. However, acute effects are generally proportional 
to baseline GFR, so they pose a more serious problem at higher GFR. In addition, we have 
shown that ARBs exert proportional treatment effects which limit statistical power of clinical 
trials using eGFR slope as end point. Solutions for these limitations include evaluation of “on 
treatment” slope rather than “total slope from randomization” and evaluation of reversal of 
acute effects following discontinuation of treatment, or both. However, as is the case with 
albuminuria there is no generally accepted method, and controversies remain. Further studies 
addressing these aspects are very important in particular since it has been shown that slowing 
progression of kidney disease at early stages of disease is more beneficial than interventions at 
later stages of disease when overt nephropathy is present.9 
The results described in this thesis were mainly obtained from analyses of clinical trials 
investigating the effect of ARBs in patients with type 2 diabetes and nephropathy. It is not clear 
how these findings will generalize to drugs of other classes. For example, it is unknown 
whether other new interventions, such as endothelin antagonists or sodium-glucose-co-
transport inhibitors exert uniform or proportional treatment effects. Thus additional research 
on the applicability of the findings described in this thesis to other drugs and interventions is 
warranted. 
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